среда, 29 июня 2016 г.

U.S. FDA panel backs claim Lilly diabetes drug

U.S. FDA panel backs claim Lilly diabetes drug


Eli Lilly & Co and Boehringer Ingelheim should be allowed to claim that their diabetes drug Jardiance cuts the risk of cardiovascular death, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. Jardiance, also known as empagliflozin, was approved in 2014 to help lower blood sugar in patients with type 2 diabetes.



from Biotech News